Compare PFO & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFO | PMN |
|---|---|---|
| Founded | 1991 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance Companies | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.3M | 115.5M |
| IPO Year | N/A | 2022 |
| Metric | PFO | PMN |
|---|---|---|
| Price | $9.28 | $12.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $42.67 |
| AVG Volume (30 Days) | 29.3K | ★ 36.4K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.01 | $0.29 |
| 52 Week High | $9.90 | $27.40 |
| Indicator | PFO | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 56.53 | 39.63 |
| Support Level | $9.16 | $0.41 |
| Resistance Level | $9.33 | $19.85 |
| Average True Range (ATR) | 0.11 | 1.46 |
| MACD | 0.05 | -0.39 |
| Stochastic Oscillator | 81.03 | 26.69 |
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.